IDH2 and central nervous system cancer: Isocitrate dehydrogenase (IDH) is a frequent mutation associated with a survival benefit in glioma patients and it has been defined as a molecular parameter to define the categories of brain tumors in the updated 2016 edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) [17].